In The News
Labiotech LSX Nordic Congress wrap-up
Drug Discovery World Clinical Trials Day
Press Releases
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
Synklino A/S, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, today announces the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).
Oral presentation of late-breaking abstract at the World Transplant Congress (“WTC”) in San Francisco taking place 2-6 August 2025
The presentation will include data on the safety and feasibility of the administration of SYN002 to human kidneys during normothermic machine perfusion (NMP), as well as data on the efficacy of eliminating latently infected cells from the treated kidneys.
Synklino Submits Clinical Trial Application to UK Authorities and Prepares for Phase 1 Study of SYN002
Synklino A/S today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its first-in-human clinical trial of SYN002.